183 related articles for article (PubMed ID: 28929345)
21. Pemafibrate, a selective PPARα modulator, and fenofibrate suppress microglial activation through distinct PPARα and SIRT1-dependent pathways.
Ogawa K; Yagi T; Guo T; Takeda K; Ohguchi H; Koyama H; Aotani D; Imaeda K; Kataoka H; Tanaka T
Biochem Biophys Res Commun; 2020 Apr; 524(2):385-391. PubMed ID: 32005522
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and metabolism of pemafibrate, a novel selective peroxisome proliferator-activated receptor-alpha modulator, in rats and monkeys.
Ogawa SI; Tsunenari Y; Kawai H; Yamazaki H
Biopharm Drug Dispos; 2019 Jan; 40(1):12-17. PubMed ID: 30517973
[TBL] [Abstract][Full Text] [Related]
23. A validated LC-MS/MS method for the low-level determination of pemafibrate, a novel SPPARMα, in plasma.
Kobuchi S; Shigemura A; Ito Y; Sakaeda T
Bioanalysis; 2020 May; 12(10):683-692. PubMed ID: 32489112
[No Abstract] [Full Text] [Related]
24. Pemafibrate Protects Against Retinal Dysfunction in a Murine Model of Diabetic Retinopathy.
Tomita Y; Lee D; Miwa Y; Jiang X; Ohta M; Tsubota K; Kurihara T
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872333
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
Atherosclerosis; 2017 Jun; 261():144-152. PubMed ID: 28410749
[TBL] [Abstract][Full Text] [Related]
26. SPPARM alpha: the Lazarus effect.
Fruchart JC; Santos RD
Curr Opin Lipidol; 2019 Dec; 30(6):419-427. PubMed ID: 31577610
[TBL] [Abstract][Full Text] [Related]
27. Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Ishibashi S; Yamashita S; Arai H; Araki E; Yokote K; Suganami H; Fruchart JC; Kodama T;
Atherosclerosis; 2016 Jun; 249():36-43. PubMed ID: 27062408
[TBL] [Abstract][Full Text] [Related]
28. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study.
Pradhan AD; Paynter NP; Everett BM; Glynn RJ; Amarenco P; Elam M; Ginsberg H; Hiatt WR; Ishibashi S; Koenig W; Nordestgaard BG; Fruchart JC; Libby P; Ridker PM
Am Heart J; 2018 Dec; 206():80-93. PubMed ID: 30342298
[TBL] [Abstract][Full Text] [Related]
29. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator K-877 (Pemafibrate) on Postprandial hyperlipidemia.
Fujioka Y
J Atheroscler Thromb; 2018 Feb; 25(2):126-127. PubMed ID: 29046503
[No Abstract] [Full Text] [Related]
30. The Effects of Pemafibrate in Japanese Patients with Type 2 Diabetes Receiving HMG-CoA Reductase Inhibitors.
Kusunoki M; Sakazaki T; Tsutsumi K; Miyata T; Oshida Y
Endocr Metab Immune Disord Drug Targets; 2021; 21(5):919-924. PubMed ID: 32819242
[TBL] [Abstract][Full Text] [Related]
31. PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003
[TBL] [Abstract][Full Text] [Related]
32. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.
Fruchart JC; Santos RD; Aguilar-Salinas C; Aikawa M; Al Rasadi K; Amarenco P; Barter PJ; Ceska R; Corsini A; Després JP; Duriez P; Eckel RH; Ezhov MV; Farnier M; Ginsberg HN; Hermans MP; Ishibashi S; Karpe F; Kodama T; Koenig W; Krempf M; Lim S; Lorenzatti AJ; McPherson R; Nuñez-Cortes JM; Nordestgaard BG; Ogawa H; Packard CJ; Plutzky J; Ponte-Negretti CI; Pradhan A; Ray KK; Reiner Ž; Ridker PM; Ruscica M; Sadikot S; Shimano H; Sritara P; Stock JK; Su TC; Susekov AV; Tartar A; Taskinen MR; Tenenbaum A; Tokgözoğlu LS; Tomlinson B; Tybjærg-Hansen A; Valensi P; Vrablík M; Wahli W; Watts GF; Yamashita S; Yokote K; Zambon A; Libby P
Cardiovasc Diabetol; 2019 Jun; 18(1):71. PubMed ID: 31164165
[TBL] [Abstract][Full Text] [Related]
33. Selective PPARα agonist pemafibrate inhibits TNF-α-induced S100A7 upregulation in keratinocytes.
Yumine A; Tsuji G; Furue M
J Dermatol Sci; 2020 Jul; 99(1):69-72. PubMed ID: 32507539
[No Abstract] [Full Text] [Related]
34. Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Arai H; Yamashita S; Yokote K; Araki E; Suganami H; Ishibashi S;
J Atheroscler Thromb; 2018 Jun; 25(6):521-538. PubMed ID: 29628483
[TBL] [Abstract][Full Text] [Related]
35. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
36. Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome.
Nakamura A; Kagaya Y; Saito H; Kanazawa M; Sato K; Miura M; Kondo M; Endo H
Heart Vessels; 2024 Jun; 39(6):486-495. PubMed ID: 38393377
[TBL] [Abstract][Full Text] [Related]
37. Effects of Pemafibrate on Reducing Oxidative Stress and Augmenting Angiogenesis in Ischemic Limb Tissue.
Anegawa T; Sasaki KI; Ishizaki Y; Negoto S; Oryoji A; Nakamura E; Otsuka H; Hiromatsu S; Fukumoto Y; Tayama E
Kurume Med J; 2024 May; 69(3.4):167-174. PubMed ID: 38233183
[TBL] [Abstract][Full Text] [Related]
38. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
Huang TH; Peng G; Li GQ; Yamahara J; Roufogalis BD; Li Y
Toxicol Appl Pharmacol; 2006 Feb; 210(3):225-35. PubMed ID: 15975614
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
Araki E; Yamashita S; Arai H; Yokote K; Satoh J; Inoguchi T; Nakamura J; Maegawa H; Yoshioka N; Tanizawa Y; Watada H; Suganami H; Ishibashi S
Diabetes Obes Metab; 2019 Jul; 21(7):1737-1744. PubMed ID: 30830727
[TBL] [Abstract][Full Text] [Related]
40. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Duez H; Lefebvre B; Poulain P; Torra IP; Percevault F; Luc G; Peters JM; Gonzalez FJ; Gineste R; Helleboid S; Dzavik V; Fruchart JC; Fiévet C; Lefebvre P; Staels B
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):585-91. PubMed ID: 15618549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
